ARTICLE | Company News
Daiichi gets $1.35B up front from AZ in antibody-drug conjugate deal
March 29, 2019 3:13 AM UTC
AstraZeneca will pay Daiichi Sankyo $1.35 billion up front to bolster one of the four platforms of its oncology unit, ADCs.
Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Friday that they will jointly develop and commercialize the Japanese pharma’s antibody-drug conjugate fam-trastuzumab deruxtecan (DS-8201) worldwide, except in Japan...